Hydroxychloroquine photosensitivity rash: Complete Guide

Hydroxychloroquine (Plaquenil) is an antimalarial drug widely used as a disease-modifying antirheumatic drug (DMARD) for lupus (SLE), rheumatoid arthritis, and Sjögren’s syndrome. This context creates a critical clinical paradox: hydroxychloroquine is the cornerstone treatment for lupus, which itself causes severe photosensitivity — yet hydroxychloroquine can occasionally cause its own photosensitivity rash.

The Paradox: HCQ Treats Photosensitivity but Can Cause It

Lupus erythematosus is strongly associated with photosensitivity — UV light triggers lupus flares, skin lesions, and systemic disease activity. Hydroxychloroquine is one of the primary treatments that reduces lupus photosensitivity by:

• Inhibiting antigen presentation by interfering with lysosomal function
• Reducing TLR7/9-mediated innate immune activation triggered by UV-induced nucleic acid release
• Providing mild UV filtering effects

Yet paradoxically, HCQ can cause its own photosensitivity rash in a small percentage of patients — most commonly a blue-grey pigmentation of sun-exposed skin and, rarely, an acute phototoxic reaction.

Types of HCQ-Related Photosensitivity

Blue-grey skin pigmentation (HCQ-induced dyspigmentation):

• The most common dermatological side effect: 4–29% of long-term users
• Blue, grey, or yellow-brown discoloration of sun-exposed skin (shins, face, hard palate)
• Caused by deposition of HCQ-melanin complexes in melanosomes — UV light triggers the binding
• Appears after months to years of use; more common with higher doses
• May be partially reversible after discontinuation but can persist

Acute phototoxic/photoallergic reaction (rare):

• Urticarial or eczematous rash in sun-exposed areas
• More common in patients with concurrent lupus photosensitivity who may have altered cutaneous photoreactivity

Distinguishing from lupus photosensitivity: This is clinically critical. If a lupus patient on HCQ develops a new rash after sun exposure, the differential includes: lupus flare, HCQ-induced reaction, or both. Dermatology or rheumatology consultation is essential.

Ocular Toxicity of Hydroxychloroquine (Critical)

The most important concern with long-term HCQ use is retinal toxicity (maculopathy), not cutaneous photosensitivity:

• Prevalence: ~7.5% with >5 years use; up to 20–50% with >20 years at higher doses
• Damages the parafoveal retina in a “bull’s-eye” pattern
• Initially asymptomatic; detected by visual field testing and optical coherence tomography (OCT)
• Irreversible and can progress even after stopping HCQ
• Annual ophthalmologic screening is mandatory for all patients on HCQ for >5 years

Retinal toxicity does not cause photophobia directly but can cause visual field loss and reduced contrast sensitivity. Patients sometimes misattribute visual symptoms to the condition for which HCQ is prescribed.

Prevention and Management

Cutaneous photosensitivity:

• Daily broad-spectrum SPF 50+ sunscreen — especially important given that these patients (lupus, RA) already have photosensitivity concerns
• Sun-protective clothing and hat
• For pigmentation: switching to a lower dose or discontinuing may slow progression; the discoloration may partially fade over years

Retinal protection:

• Baseline eye exam before starting HCQ or within the first year
• Annual dilated fundus exam and visual field testing after 5 years of use
• OCT imaging for early detection of subclinical maculopathy
• Dose should not exceed 5mg/kg/day to minimize retinal risk

Sources

1. Marmor MF, et al. “Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.” Ophthalmology. 2011;118(2):415-422.
2. Dubois EL. “Antimalarials in the management of discoid and systemic lupus erythematosus.” Semin Arthritis Rheum. 1978;8(1):33-51.
3. Sontheimer RD. “Photoimmunology of lupus erythematosus and dermatomyositis.” Photodermatol Photoimmunol Photomed. 2004;20(2):272-279.